Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD‐1 inhibitors (T‐L‐P) versus TACE...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Wei‐Jun Wang, Zong‐Han Liu, Kang Wang, Hong‐Ming Yu, Yu‐Qiang Cheng, Yan‐Jun Xiang, Jin‐Kai Feng, Li‐Ping Zhou, Hong‐Kun Zhou, Wei‐Wei Pan, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2023-05-01
Serie:	Cancer Medicine
Soggetti:	combination therapy hepatocellular carcinoma (HCC) lenvatinib programmed death‐1 recurrent transarterial chemoembolization (TACE)
Accesso online:	https://doi.org/10.1002/cam4.5880
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!